tickertape
← runs

ABBV

AbbVie Inc.eval run
10-K for period ending 2025-12-31gpt-6-luna@none · prompt v4$0.00095.4sfiling on sec.gov ↗

figures

fieldvaluestatement rowprintedSEC
Total revenue$61.2BR1 Net revenues61,160 millions$61.2B ✓
Operating income$15.1BR8 Operating earnings15,075 millions$15.1B ✓
Net income attributable to the company$4.2BR16 Net earnings attributable to AbbVie Inc.4,226 millions$4.2B ✓
Diluted EPS$2.36R19 Diluted earnings per share attributable to AbbVie Inc.2.36$2.36 ✓
Cash and cash equivalents$5.2BR3 Cash and equivalents5,229 millions$5.2B ✓
Total assets$134.0BR14 Total assets133,960 millions$134.0B ✓
Total liabilities-not printed on this statement--
Total shareholders' equity attributable to the company-$3.3BR31 Total stockholders' equity (deficit)(3,270) millions-$3.3B ✓
Net cash from operating activities$19.0BR20 Cash flows from operating activities19,030 millions$19.0B ✓
Net cash from investing activities-$6.6BR28 Cash flows from investing activities(6,643) millions-$6.6B ✓
Net cash from financing activities-$12.7BR41 Cash flows from financing activities(12,724) millions-$12.7B ✓

checks

  • assets = liabilities + equity · total assets equals total liabilities and equity
  • equity excludes minority interests · totalEquity excludes noncontrolling interests
  • net income is before preferred dividends · net income is not the after-preferred-dividends line
  • diluted EPS is for total net income · diluted EPS is for total net income
  • net income excludes minority interests · netIncome excludes noncontrolling interests
  • cash flows tie to the change in cash · operating + investing + financing (+ FX) equals the net change in cash

management's claims

Found 5 claims, none about a company-wide figure the statements can confirm.

trace

  1. 0locator (code)0.18s
    {
  "tables": 215,
  "exhibits": [],
  "documents": 1
}
    {
  "income": {
    "rows": 22,
    "scale": 1000000,
    "score": 50.25,
    "heading": "AbbVie Inc. and Subsidiaries Consolidated Statements of Earnings",
    "tableIndex": 80,
    "runnerUpScore": 30
  },
  "balance": {
    "rows": 35,
    "scale": 1000000,
    "score": 52.25,
    "heading": "AbbVie Inc. and Subsidiaries Consolidated Balance Sheets",
    "tableIndex": 84,
    "runnerUpScore": 20.5
  },
  "cashflow": {
    "rows": 48,
    "scale": 1000000,
    "score": 55,
    "heading": "AbbVie Inc. and Subsidiaries Consolidated Statements of Cash Flows",
    "tableIndex": 88,
    "runnerUpScore": 10
  }
}
  2. 1cash flow agent1.63s · 1684 tokens · $0.0002
    {
  "rows": 48,
  "retryHint": null,
  "tableIndex": 88
}
    {
  "figures": [
    {
      "note": "This is the operating-activities section total, after changes in operating assets and liabilities.",
      "field": "operatingCashFlow",
      "scale": 1000000,
      "value": 19030000000,
      "printed": "19,030",
      "rowIndex": 20,
      "rowLabel": "Cash flows from operating activities",
      "priorValue": 18806000000,
      "agentPrinted": "19,030",
      "failedChecks": [],
      "priorPrinted": "18,806",
      "groundingMismatch": false
    },
    {
      "note": "This is the printed investing-activities section total.",
      "field": "investingCashFlow",
      "scale": 1000000,
      "value": -6643000000,
      "printed": "(6,643)",
      "rowIndex": 28,
      "rowLabel": "Cash flows from investing activities",
      "priorValue": -20820000000,
      "agentPrinted": "(6,643)",
      "failedChecks": [],
      "priorPrinted": "(20,820)",
      "groundingMismatch": false
    },
    {
      "note": "This is the printed financing-activities section total.",
      "field": "financingCashFlow",
      "scale": 1000000,
      "value": -12724000000,
      "printed": "(12,724)",
      "rowIndex": 41,
      "rowLabel": "Cash flows from financing activities",
      "priorValue": -5211000000,
      "agentPrinted": "(12,724)",
      "failedChecks": [],
      "priorPrinted": "(5,211)",
      "groundingMismatch": false
    }
  ],
  "statement": "cashflow",
  "tableIndex": 88,
  "priorColumn": 1,
  "currentColumn": 0
}
  3. 2income statement agent1.72s · 1478 tokens · $0.0002
    {
  "rows": 22,
  "retryHint": null,
  "tableIndex": 80
}
    {
  "figures": [
    {
      "note": "Net revenues is the company-wide revenue total.",
      "field": "revenue",
      "scale": 1000000,
      "value": 61160000000,
      "printed": "61,160",
      "rowIndex": 1,
      "rowLabel": "Net revenues",
      "priorValue": 56334000000,
      "agentPrinted": "61,160",
      "failedChecks": [],
      "priorPrinted": "56,334",
      "groundingMismatch": false
    },
    {
      "note": "Operating earnings is the statement’s operating income line.",
      "field": "operatingIncome",
      "scale": 1000000,
      "value": 15075000000,
      "printed": "15,075",
      "rowIndex": 8,
      "rowLabel": "Operating earnings",
      "priorValue": 9137000000,
      "agentPrinted": "15,075",
      "failedChecks": [],
      "priorPrinted": "9,137",
      "groundingMismatch": false
    },
    {
      "note": "This line reports net earnings attributable to AbbVie Inc., excluding noncontrolling interests.",
      "field": "netIncome",
      "scale": 1000000,
      "value": 4226000000,
      "printed": "4,226",
      "rowIndex": 16,
      "rowLabel": "Net earnings attributable to AbbVie Inc.",
      "priorValue": 4278000000,
      "agentPrinted": "4,226",
      "failedChecks": [],
      "priorPrinted": "4,278",
      "groundingMismatch": false
    },
    {
      "note": "This is diluted earnings per share attributable to AbbVie Inc.",
      "field": "epsDiluted",
      "scale": 1,
      "value": 2.36,
      "printed": "2.36",
      "rowIndex": 19,
      "rowLabel": "Diluted earnings per share attributable to AbbVie Inc.",
      "priorValue": 2.39,
      "agentPrinted": "2.36",
      "failedChecks": [],
      "priorPrinted": "2.39",
      "groundingMismatch": false
    }
  ],
  "statement": "income",
  "tableIndex": 80,
  "priorColumn": 1,
  "currentColumn": 0
}
  4. 3balance sheet agent1.78s · 1401 tokens · $0.0002
    {
  "rows": 35,
  "retryHint": null,
  "tableIndex": 84
}
    {
  "figures": [
    {
      "note": "This is the printed cash and equivalents line.",
      "field": "cash",
      "scale": 1000000,
      "value": 5229000000,
      "printed": "5,229",
      "rowIndex": 3,
      "rowLabel": "Cash and equivalents",
      "priorValue": 5524000000,
      "agentPrinted": "5,229",
      "failedChecks": [],
      "priorPrinted": "5,524",
      "groundingMismatch": false
    },
    {
      "note": "This is the printed total assets line.",
      "field": "totalAssets",
      "scale": 1000000,
      "value": 133960000000,
      "printed": "133,960",
      "rowIndex": 14,
      "rowLabel": "Total assets",
      "priorValue": 135161000000,
      "agentPrinted": "133,960",
      "failedChecks": [],
      "priorPrinted": "135,161",
      "groundingMismatch": false
    },
    {
      "note": "The statement does not print a total liabilities line.",
      "field": "totalLiabilities",
      "scale": 1000000,
      "value": null,
      "printed": null,
      "rowIndex": null,
      "rowLabel": null,
      "priorValue": null,
      "agentPrinted": null,
      "failedChecks": [],
      "priorPrinted": null,
      "groundingMismatch": false
    },
    {
      "note": "This is stockholders' equity attributable to the company, excluding noncontrolling interest.",
      "field": "totalEquity",
      "scale": 1000000,
      "value": -3270000000,
      "printed": "(3,270)",
      "rowIndex": 31,
      "rowLabel": "Total stockholders' equity (deficit)",
      "priorValue": 3325000000,
      "agentPrinted": "(3,270)",
      "failedChecks": [],
      "priorPrinted": "3,325",
      "groundingMismatch": false
    }
  ],
  "statement": "balance",
  "tableIndex": 84,
  "priorColumn": 1,
  "currentColumn": 0
}
  5. 4reconciler (code)0.00s
    null
    [
  {
    "name": "balance_identity",
    "detail": "total assets equals total liabilities and equity",
    "fields": [
      "totalAssets"
    ],
    "passed": true,
    "skipped": false,
    "statement": "balance"
  },
  {
    "name": "totalEquity_attribution",
    "detail": "totalEquity excludes noncontrolling interests",
    "fields": [
      "totalEquity"
    ],
    "passed": true,
    "skipped": false,
    "statement": "balance"
  },
  {
    "name": "netIncome_before_preferred",
    "detail": "net income is not the after-preferred-dividends line",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "epsDiluted_total",
    "detail": "diluted EPS is for total net income",
    "fields": [
      "epsDiluted"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "netIncome_attribution",
    "detail": "netIncome excludes noncontrolling interests",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "cash_flow_tie",
    "detail": "operating + investing + financing (+ FX) equals the net change in cash",
    "fields": [
      "operatingCashFlow",
      "investingCashFlow",
      "financingCashFlow"
    ],
    "passed": true,
    "skipped": false,
    "statement": "cashflow"
  }
]
  6. 5MD&A claims agent3.18s · 1584 tokens · $0.0003
    null
    [
  {
    "kind": "current_value",
    "field": "revenue",
    "quote": "The company's financial performance in 2025 included delivering worldwide net revenues of $61.2 billion, operating earnings of $15.1 billion, diluted earnings per share of $2.36 and cash flows from operations of $19.0 billion.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Total revenue: the sentence is about a region, segment or adjusted measure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "$61.2 billion",
    "tolerance": null,
    "quoteVerified": true
  },
  {
    "kind": "current_value",
    "field": "operatingIncome",
    "quote": "The company's financial performance in 2025 included delivering worldwide net revenues of $61.2 billion, operating earnings of $15.1 billion, diluted earnings per share of $2.36 and cash flows from operations of $19.0 billion.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Operating income: the sentence is about a region, segment or adjusted measure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "$15.1 billion",
    "tolerance": null,
    "quoteVerified": true
  },
  {
    "kind": "current_value",
    "field": "epsDiluted",
    "quote": "The company's financial performance in 2025 included delivering worldwide net revenues of $61.2 billion, operating earnings of $15.1 billion, diluted earnings per share of $2.36 and cash flows from operations of $19.0 billion.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Diluted EPS: the sentence is about a region, segment or adjusted measure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "$2.36",
    "tolerance": null,
    "quoteVerified": true
  },
  {
    "kind": "current_value",
    "field": "operatingCashFlow",
    "quote": "The company's financial performance in 2025 included delivering worldwide net revenues of $61.2 billion, operating earnings of $15.1 billion, diluted earnings per share of $2.36 and cash flows from operations of $19.0 billion.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Net cash from operating activities: the sentence doesn't name this figure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "$19.0 billion",
    "tolerance": null,
    "quoteVerified": true
  },
  {
    "kind": "percent_change",
    "field": "revenue",
    "quote": "Worldwide net revenues increased by 9% on a reported and on a constant currency basis.",
    "scope": "consolidated",
    "actual": null,
    "reason": "Total revenue: the sentence is about a region, segment or adjusted measure",
    "claimed": null,
    "verdict": "not_checked",
    "asWritten": "9%",
    "tolerance": null,
    "quoteVerified": true
  }
]

Income statement

table #80 · current period is figure column 1
0years ended December 31 (in millions, except per share data)202520242023
1Net revenues← Total revenue61,16056,33454,318
2Cost of products sold18,20416,90420,415
3Selling, general and administrative14,01014,75212,872
4Research and development9,09612,7917,675
5Acquired IPR&D and milestones5,0162,757778
6Other operating income(241)(7)(179)
7Total operating costs and expenses46,08547,19741,561
8Operating earnings← Operating income15,0759,13712,757
9Interest expense, net2,6272,1601,684
10Net foreign exchange loss5821146
11Other expense, net5,7933,2404,677
12Earnings before income tax expense6,5973,7166,250
13Income tax expense (benefit)2,364(570)1,377
14Net earnings4,2334,2864,873
15Net earnings attributable to noncontrolling interest7810
16Net earnings attributable to AbbVie Inc.← Net income attributable to the company4,2264,2784,863
17Per share data
18Basic earnings per share attributable to AbbVie Inc.2.372.402.73
19Diluted earnings per share attributable to AbbVie Inc.← Diluted EPS2.362.392.72
20Weighted-average basic shares outstanding1,7691,7691,768
21Weighted-average diluted shares outstanding1,7731,7731,773

Balance sheet

table #84 · current period is figure column 1
0as of December 31 (in millions, except share data)20252024
1Assets
2Current assets
3Cash and equivalents← Cash and cash equivalents5,2295,524
4Short-term investments2831
5Accounts receivable, net12,58910,919
6Inventories4,9514,181
7Prepaid expenses and other6,2654,927
8Total current assets29,06225,582
9Investments268279
10Property and equipment, net5,6285,134
11Intangible assets, net52,64160,068
12Goodwill35,64034,956
13Other assets10,7219,142
14Total assets← Total assets133,960135,161
15Liabilities and Equity
16Current liabilities
17Short-term borrowings2,499-
18Current portion of long-term debt and finance lease obligations6,0566,804
19Accounts payable and accrued liabilities34,73431,945
20Total current liabilities43,28938,749
21Long-term debt and finance lease obligations58,94160,340
22Deferred income taxes2,3892,579
23Other long-term liabilities32,56930,129
24Commitments and contingencies
25Stockholders' equity (deficit)
26Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,838,678,628 shares issued as of December 31, 2025 and 1,831,594,494 as of December 31, 20241818
27Common stock held in treasury, at cost, 70,802,593 shares as of December 31, 2025 and 66,337,508 as of December 31, 2024(9,146)(8,201)
28Additional paid-in capital22,49521,333
29Accumulated deficit(15,493)(7,900)
30Accumulated other comprehensive loss(1,144)(1,925)
31Total stockholders' equity (deficit)← Total shareholders' equity attributable to the company(3,270)3,325
32Noncontrolling interest4239
33Total equity (deficit)(3,228)3,364
34Total liabilities and equity133,960135,161

Cash flow statement

table #88 · current period is figure column 1
0years ended December 31 (in millions) (brackets denote cash outflows)202520242023
1Cash flows from operating activities
2Net earnings4,2334,2864,873
3Adjustments to reconcile net earnings to net cash from operating activities:
4Depreciation762764752
5Amortization of intangible assets7,3777,6227,946
6Deferred income taxes(492)(1,449)(2,889)
7Change in fair value of contingent consideration liabilities6,4953,7715,128
8Payments of contingent consideration liabilities(2,865)(1,995)(870)
9Stock-based compensation955911747
10Acquired IPR&D and milestones5,0162,757778
11Non-cash litigation reserve adjustments, net of cash payments(933)508(443)
12Impairment of intangible assets8474,4764,229
13Other, net(3)(63)(225)
14Changes in operating assets and liabilities, net of acquisitions:
15Accounts receivable(1,490)20766
16Inventories(234)(319)(417)
17Prepaid expenses and other assets(827)361(188)
18Accounts payable and other liabilities9511773,840
19Income tax assets and liabilities, net(762)(3,208)(488)
20Cash flows from operating activities← Net cash from operating activities19,03018,80622,839
21Cash flows from investing activities
22Acquisition of businesses, net of cash acquired(204)(17,493)-
23Other acquisitions and investments, net of cash acquired(5,237)(3,024)(1,223)
24Acquisitions of property and equipment(1,214)(974)(777)
25Purchases of investment securities(35)(73)(77)
26Sales and maturities of investment securities7655555
27Other, net(29)18913
28Cash flows from investing activities← Net cash from investing activities(6,643)(20,820)(2,009)
29Cash flows from financing activities
30Net change in commercial paper borrowings with original maturities of three months or less499--
31Proceeds from issuance of other short-term borrowings4,7985,008-
32Repayments of other short-term borrowings(2,798)(5,008)-
33Proceeds from issuance of long-term debt3,99416,963-
34Repayments of long-term debt and finance lease obligations(6,797)(9,613)(4,149)
35Debt issuance costs(23)(99)(38)
36Dividends paid(11,657)(11,025)(10,539)
37Purchases of treasury stock(980)(1,708)(1,972)
38Proceeds from the exercise of stock options172214180
39Payments of contingent consideration liabilities--(752)
40Other, net685748
41Cash flows from financing activities← Net cash from financing activities(12,724)(5,211)(17,222)
42Effect of exchange rate changes on cash and equivalents42(65)5
43Net change in cash and equivalents(295)(7,290)3,613
44Cash and equivalents, beginning of year5,52412,8149,201
45Cash and equivalents, end of year5,2295,52412,814
46Other supplemental information
47Interest paid, net of portion capitalized3,0022,8112,469